Kistik Fibrozisli Hastalarda Lactobacillus Rhamnosus Gg Desteğinin Gastrointestinal Sistem ve Pulmoner İnflamasyon ile Beslenme Durumuna Etkisi

Abstract

Serçe, H. The Effect of Lactobacillus Rhamnosus GG Support on Gastrointestinal System and Pulmonary Inflammation and Nutrition Status in Patients with Cystic Fibrosis. Hacettepe University Institute of Health Sciences, Nutrition and Dietetics Program, Doctoral Thesis, Ankara, 2021. In this study, it was aimed to investigate the effect of Lactobacillus rhamnosus GG probiotic supplementation on nutritional status with markers of intestinal inflammation and pulmonary inflammation in patients with cystic fibrosis. In a randomized, controlled study, 36 patients with cystic fibrosis (male=19, female=17) with a mean age of 12±3,4 years (between the ages of 6 and 18) were randomly divided into 2 groups as equal numbers of probiotics (n=18) and controls (n=18). The patients in the probiotic group were given 1 capsule (6x109 cfu) Lactobacillus rhamnosus GG probiotic supplement daily for 90 days. At the beginning and at the end of the study, food consumption records, anthropometric measurements, blood and stool samples of the patients were taken, sputum culture and %FEV1 measurements were examined. At the end of the intervention, no significant difference was found between probiotic and control group patients in serum total protein, albumin, prealbumin, TNF-α, IL-6, IL-1β, IgG, IgM, %FEV1 levels and sputum cultures (p >0.05). There was an increase in anthropometric measurements compared to before the intervention, but the difference between the groups was not significant (p >0.05). While IL-8 level decreased significantly in the probiotic group after the intervention, it increased in the control group (p =0.03). The proportion of patients with high IL-17 levels decreased in the probiotic group after the intervention compared to the control group, but was not found to be significant (p >0.05). Fecal calprotectin level decreased in the probiotic group after the intervention and increased in the control group, but the difference between the groups before and after the intervention was not significant (p =0.5). These findings suggest that Lactobacillus rhamnosus GG probiotic supplementation may reduce serum IL-8, IL-17 and fecal calprotectin levels in patients with cystic fibrosis. As a result, although the data are insufficient to specify the species, strain, dose recommendation or duration of use for probiotic support in routine treatment, the therapeutic properties of probiotics are a very important approach. Keywords: Cystic fibrosis, probiotic, inflammation, interleukin, nutrition. Supporting Institutions: This study was supported by Hacettepe University Scientific Research Projects Coordination Unit (Project no: THD-2019-18415).